Institution
Case Western Reserve University
Education•Cleveland, Ohio, United States•
About: Case Western Reserve University is a education organization based out in Cleveland, Ohio, United States. It is known for research contribution in the topics: Population & Health care. The organization has 54617 authors who have published 106568 publications receiving 5071613 citations. The organization is also known as: Case & Case Western.
Topics: Population, Health care, Cancer, Transplantation, Poison control
Papers published on a yearly basis
Papers
More filters
••
615 citations
••
TL;DR: In this article, the authors examined the effects of social ostracism on individuals' subsequent contributions to a group task and found that ostracized individuals to socially compensate-to work harder collectively than coactively.
Abstract: A new theoretical model and research paradigm are introduced to investigate the phenomenon of social ostracism-being ignored by others who are in one's presence. The authors examined the effects of social ostracism on individuals' subsequent contributions to a group task. Social loafing Optically occurs on collective tasks. However; to regain their sense of belonging to the group, the authors expected ostracized individuals to socially compensate-to work harder collectively than coactively. Participants were asked to generate as many uses as they could for an object, either coactively or collectively with two others who had either ostracized or included them in an earlier ball-tossing exchange. Ostracized females socially compensated, whereas nonostracized females neither loafed nor compensated. Ostracized and nonostracized males socially loafed. Based on these data and the accompanying attributional and nonverbal analyses, the authors surmised that males and females interpret and respond to social ostrac...
614 citations
••
TL;DR: Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode.
Abstract: Background Lamotrigine has been shown to be an effective treatment for bipolar depression and rapid cycling in placebo-controlled clinical trials. This double-blind, placebo-controlled study was conducted to assess the efficacy and tolerability of lamotrigine and lithium compared with placebo for the prevention of relapse or recurrence of mood episodes in recently manic or hypomanic patients with bipolar I disorder. Methods After an 8- to 16-week open-label phase during which treatment with lamotrigine was initiated and other psychotropic drug regimens were discontinued, patients were randomized to lamotrigine (100-400 mg daily), lithium (0.8-1.1 mEq/L), or placebo as double-blind maintenance treatment for as long as 18 months. Results Of 349 patients who met screening criteria and entered the open-label phase, 175 met stabilization criteria and were randomized to double-blind maintenance treatment (lamotrigine, 59 patients; lithium, 46 patients; and placebo, 70 patients). Both lamotrigine and lithium were superior to placebo at prolonging the time to intervention for any mood episode (lamotrigine vs placebo, P = .02; lithium vs placebo, P = .006). Lamotrigine was superior to placebo at prolonging the time to a depressive episode ( P = .02). Lithium was superior to placebo at prolonging the time to a manic, hypomanic, or mixed episode( P =.006). The most common adverse event reported for lamotrigine was headache. Conclusions Both lamotrigine and lithium were superior to placebo for the prevention of relapse or recurrence of mood episodes in patients with bipolar I disorder who had recently experienced a manic or hypomanic episode. The results indicate that lamotrigine is an effective, well-tolerated maintenance treatment for bipolar disorder, particularly for prophylaxis of depression.
614 citations
••
TL;DR: Tight glucose control significantly decreases DKD incidence, indicating that hyperglycemia-induced metabolic alterations, including changes in energy utilization and mitochondrial dysfunction, play critical roles in disease initiation.
Abstract: Diabetic kidney disease (DKD) is the leading cause of kidney failure worldwide and the single strongest predictor of mortality in patients with diabetes. DKD is a prototypical disease of gene and environmental interactions. Tight glucose control significantly decreases DKD incidence, indicating that hyperglycemia-induced metabolic alterations, including changes in energy utilization and mitochondrial dysfunction, play critical roles in disease initiation. Blood pressure control, especially with medications that inhibit the angiotensin system, is the only effective way to slow disease progression. While DKD is considered a microvascular complication of diabetes, growing evidence indicates that podocyte loss and epithelial dysfunction play important roles. Inflammation, cell hypertrophy, and dedifferentiation by the activation of classic pathways of regeneration further contribute to disease progression. Concerted clinical and basic research efforts will be needed to understand DKD pathogenesis and to identify novel drug targets.
613 citations
••
TL;DR: Cystic fibrosis (CF) was distinguished from celiac disease in 1938 as mentioned in this paper and was considered a pathologic diagnosis, life expectancy was approximately 6 months, and the autosomal recessive disease was believed to arise from abnormal mucus plugging exocrine ducts.
Abstract: Cystic fibrosis (CF) was distinguished from celiac disease in 1938. Then, it was a pathologic diagnosis, life expectancy was approximately 6 months, and the autosomal recessive disease was believed to arise from abnormal mucus plugging exocrine ducts. Death often occurred from lung infection. Discovery of the sweat electrolyte defect in 1953 and standardization of the sweat test in 1959 allowed identification of milder cases, and CF was no longer considered only a disorder of mucus. In 1955, establishment of centers with programs of aggressive, comprehensive care initiated striking improvement in longevity. The pillars of care established then (attention to nutrition, airway clearance, treatment of lung infection) remain today. In 1983, chloride transport was identified as the basic physiologic CF defect, accompanied by increased sodium reabsorption. In 1980, we learned that inflammation contributes independently to lung disease and constitutes an independent therapeutic target. In 1989, the discovery of the CF gene demonstrated the basic defect to be in a cAMP-regulated chloride channel. This afforded new diagnostic tests, opportunities for research, and prospects for using the gene as therapy. Since then, substantial advances in basic and clinical research catalyzed therapeutic improvements: median survival age now exceeds 30 years. The Cystic Fibrosis Foundation center network provides not only opportunity to conduct clinical trials but also means to disseminate new therapies. In the future, treatments directed at the basic defect can be expected, with concomitant improvements in morbidity and mortality.
613 citations
Authors
Showing all 54953 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Bert Vogelstein | 247 | 757 | 332094 |
Zhong Lin Wang | 245 | 2529 | 259003 |
John Q. Trojanowski | 226 | 1467 | 213948 |
Kenneth W. Kinzler | 215 | 640 | 243944 |
Peter Libby | 211 | 932 | 182724 |
David Baltimore | 203 | 876 | 162955 |
Carlo M. Croce | 198 | 1135 | 189007 |
Ronald Klein | 194 | 1305 | 149140 |
Eric J. Topol | 193 | 1373 | 151025 |
Paul M. Thompson | 183 | 2271 | 146736 |
Yusuke Nakamura | 179 | 2076 | 160313 |
Dennis J. Selkoe | 177 | 607 | 145825 |
David L. Kaplan | 177 | 1944 | 146082 |
Evan E. Eichler | 170 | 567 | 150409 |